A spin out company from Google has just raised a major new round of funding. And they’re aiming to use it to disrupt the future of drug discovery.

‍What’s happening:‍

  • Biotechnology company Isomorphic Labs has raised $600M USD in their first ever financing round

Why it matters:‍

  • Isomorphic Labs was originally incubated within Google’s DeepMind prior to being spun out as its own independent company

Going deeper:‍

  • The new funding round was led by Thrive Capital and included participation from Google Ventures
  • Isomorphic Labs leverages DeepMind’s AlphaFold artificial intelligence model, which is able to precisely predict protein structures and unlock new breakthroughs for complex drug discovery

The intrigue:‍

  • Publicly traded pharmaceutical giants have already cut partnerships with Isomorphic Labs to collaborate on new drug development, including both Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS)

‍